Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v12-EN Version v4-EN
Language English English
Date Updated 2022-10-03 2022-06-27
Drug Identification Number 02439387 02439387
Brand name ROPIVACAINE HYDROCHLORIDE INJECTION, USP ROPIVACAINE HYDROCHLORIDE INJECTION, USP
Common or Proper name Ropivacaine Hydrochloride Injection, USP 5 mg/mL Ampoule 10mL Ropivacaine Hydrochloride Injection, USP 5 mg/mL Ampoule 10mL
Company Name FRESENIUS KABI CANADA LTD FRESENIUS KABI CANADA LTD
Ingredients ROPIVACAINE HYDROCHLORIDE ROPIVACAINE HYDROCHLORIDE
Strength(s) 5MG 5MG
Dosage form(s) SOLUTION SOLUTION
Route of administration EPIDURAL BLOCK/INFILTRATION EPIDURAL BLOCK/INFILTRATION EPIDURAL BLOCK/INFILTRATION EPIDURAL BLOCK/INFILTRATION
Packaging size 10mL 5
ATC code N01BB N01BB
ATC description ANESTHETICS, LOCAL ANESTHETICS, LOCAL
Reason for shortage Other (Please describe in comments) Disruption of the manufacture of the drug.
Anticipated start date 2022-04-01 2022-04-01
Actual start date 2022-04-01 2022-04-01
Estimated end date 2022-10-01 2022-07-22
Actual end date 2022-09-27
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments Fresenius Kabi Canada regrets to advise that due to unforeseen circumstances, we will be extending the backorder on our Ropivacaine Hydrochloride Injection, USP 5 mg/mL Ampoule 10 mL until October 1, 2022. Backorder effective Apr. 1, 2022 until Jul. 1, 2022. Please note all available inventory of 5 mg/mL Ampoule 10mL expires March 31, 2022.
Health Canada comments